Disclosure under Regulation 30
ABBOTINDIA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.2 pts less than Nifty Midcap 150 and 1.5 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Abbott India received a Compounding Order from the RBI's Foreign Exchange Department dated July 31, 2025, closing a long-pending matter related to foreign investment exceeding the 75% sectoral cap due to secondary market share purchases. The RBI has directed the company to pay a compounding amount of Rs. 2,00,000 (Two Lakhs), which the company will deposit. The contravention occurred because foreign holdings crossed the 75% limit through stock exchange secondary market transactions without prior Government approval under FEMA rules. The closure of this compounding process will now allow Abbott India to receive fresh foreign institutional investor (FII) investments up to the prescribed statutory limit.
The penalty is negligible (Rs. 2 lakhs) relative to Abbott India's size, so there is no meaningful financial impact. More importantly, the resolution removes a regulatory overhang and reopens the door for FII buying, which is mildly positive for the stock and shareholder value.